FDA Delays Afrezza Decision by Three Months, MannKind Shares Slump

FDA Delays Afrezza Decision by Three Months, MannKind Shares Slump

While the decision comes days after a third-party group recommended the U.S. Food and Drug Administration vote in favor of marketing approval, the three-month delay was expected to provide the FDA ample to review the mounds of data submitted by …

4
Like
Save

Comments

Write a comment

*